Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 4, 2014, Pages 441-448

  Cox, Helen ^a,b   Hughes, J ^a   Daniels, J ^a   Azevedo, V ^c   McDermid, C ^a   Poolman, M ^d   Boulle, A ^b   Goemaere, E ^a,b   Van Cutsem, G ^a,b  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c City of Cape Town   (South Africa)

^d Western Cape Education Department   (South Africa)

Author keywords

Ambulatory; MDR TB; Outcomes; Treatment

Indexed keywords

RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ARTICLE; COMMUNITY CARE; COMMUNITY PROGRAM; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG RESISTANT TUBERCULOSIS; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEASIBILITY STUDY; FEMALE; HEALTH SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT MONITORING; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; SOCIAL SUPPORT; SOUTH AFRICA; SURVIVAL TIME; TREATMENT DURATION; TUBERCULOSIS; TUBERCULOSIS CONTROL; DRUG EFFECTS; EPIDEMIOLOGY; HIV INFECTIONS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIXED INFECTION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PILOT STUDY; PREVALENCE; PROGRAM EVALUATION; RETROSPECTIVE STUDY; SPUTUM; TIME; TIME TO TREATMENT; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; COINFECTION; COMMUNITY HEALTH SERVICES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEASIBILITY STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MYCOBACTERIUM TUBERCULOSIS; PILOT PROJECTS; PREVALENCE; PROGRAM EVALUATION; RETROSPECTIVE STUDIES; SOUTH AFRICA; SPUTUM; TIME FACTORS; TIME-TO-TREATMENT; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; URBAN HEALTH SERVICES; YOUNG ADULT;

EID: 84897147383     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0742     Document Type: Article

References (31)

1. World Health Organization. Global tuberculosis control: WHO report 2011. WHO/HTM/TB/2011.16. Geneva, Switzerland: WHO, 2011.
2. World Health Organization. Global tuberculosis control, 2012. WHO/HTM/TB/2012.6. Geneva, Switzerland: WHO, 2012.
3. Keshavjee S, Farmer P E. Picking up the pace - scale-up of MDR tuberculosis treatment programs. N Engl J Med 2010; 363: 1781-1784.
4. World Health Organization. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015: WHO Progress Report 2011. WHO/HTM/TB/2011.3. Geneva, Switzerland: WHO, 2011.
5. Farley J E, Ram M, Pan W, et al. Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence. PLOS ONE 2011; 6: e20436.
6. Narasimooloo R, Ross A. Delay in commencing treatment for MDR-TB at a specialised TB treatment centre in KwaZulu-Natal. S Afr Med J 2012; 102: 360-362.
7. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128. (Pubitemid 36056718)
8. Shin S, Furin J, Bayona J, Mate K, Kim J Y, Farmer P. Community-based treatment of multidrug-resistant tuberculosis in Lima, Peru: 7 years of experience. Soc Sci Med 2004; 59: 1529-1539. (Pubitemid 38891418)
9. Brust J C, Shah N S, Scott M, et al. Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care. Int J Tuberc Lung Dis 2012; 16: 998-1004.
10. Malla P, Kanitz E E, Akhtar M, et al. Ambulatory-based standardized therapy for multi-drug resistant tuberculosis: experience from Nepal, 2005-2006. PLOS ONE 2009; 4: e8313.
11. Orenstein E W, Basu S, Shah N S, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
12. Isaakidis P, Cox H S, Varghese B, et al. Ambulatory multidrug-resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, India. PLOS ONE 2011; 6: e28066.
13. Palacios E, Franke M, Munoz M, et al. HIV-positive patients treated for multidrug-resistant tuberculosis: clinical outcomes in the HAART era. Int J Tuberc Lung Dis 2012; 16: 348-354.
14. Seung K J, Omatayo D B, Keshavjee S, Furin J J, Farmer P E, Satti H. Early outcomes of MDR-TB treatment in a high HIV-Community-prevalence setting in Southern Africa. PLOS ONE 2009; 4: e7186.
15. Strategic Development Information and GIS Department City of Cape Town. 2011 Census: Khayelitsha Health District. Cape Town, South Africa: CoCT, 2013.
16. Western Cape Department of Health. Western Cape antenatal HIV survey 2010. Cape Town, South Africa: DoH, 2010.
17. Médecins Sans Frontières. Khayelitsha 2001-2011, Activity Report: 10 years of HIV-TB care at primary health care level. Khayelitsha, South Africa: MSF, 2011.
18. Cox H S, McDermid C, Azevedo V, et al. Epidemic levels of drug-resistant tuberculosis (MDR- and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa. PLOS ONE 2010; 5: e13901.
19. Médecins Sans Frontières. Scaling up diagnosis and treatment of drug-resistant tuberculosis in Khayelitsha, South Africa. Khayelitsha, South Africa: MSF, 2011.
20. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman M E. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 2008; 177: 787-792. (Pubitemid 351490566)
21. World Health Organization, Stop TB Department. Update: implementation and roll-out of Xpert MTB/RIF. Geneva, Switzerland: WHO, 2012.
22. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: Emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO 2008.
23. Department of Health South Africa. Management of drug-resistant tuberculosis: policy guidelines. Pretoria, South Afica: Department of Health, 2011.
24. Boulle A, Van Cutsem G, Hilderbrand K, et al. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS 2010; 24: 563-572.
25. Singla R, Sarin R, Khalid U K, et al. Seven-year DOTS-Plus pilot experience in India: results, constraints and issues. Int J Tuberc Lung Dis 2009; 13: 976-981.
26. Ebonwu J I, Tint K S, Ihekweazu C. Low treatment initiation rates among multidrug-resistant tuberculosis patients in Gauteng, South Africa, 2011. Int J Tuberc Lung Dis 2013; 17: 1043-1048.
27. World Health Organization. Global tuberculosis report, 2013. WHO/HTM/TB/2013.11. Geneva, Switzerland: WHO, 2013.
28. Gandhi N R, Shah N S, Andrews J R, et al. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2010; 181: 80-86.
29. Kvasnovsky C L, Cegielski J P, Erasmus R, Siwisa N O, Thomas K, der Walt ML. Extensively drug-resistant TB in Eastern Cape, South Africa: high mortality in HIV-negative and HIV-positive patients. J Acquir Immune Defic Syndr 2011; 57: 146-152.
30. Zumla A, Abubakar I, Raviglione M, et al. Drug-resistant tuberculosis-current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis 2012; 205 (Suppl 2): S228-S240.
31. Tocsek A, Cox H, du Cross P, Cooke G, Ford N. Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis 2013; 17: 299-307.